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BACKGROUND. The role of the epidermal growth factor receptor (ErbB1) in the progression
of prostate cancer is incompletely understood.
METHODS. Tissue microarrays from hormone-naive and advanced androgen-independent
tumors were used to investigate the role of ErbB1 in prostate cancer progression.
RESULTS. ErbB1 expression in tumor tissues was strongly associated with hormone-
refractory status (odds ratio¼ 6.67, 95% CI¼ (2.6, 17.4), P¼ 0.0001). However, ErbB1 over-
expression was not a statistically significant covariate in a multivariate proportional hazards
model for biochemical failure of hormone-naı̈ve prostate cancer. Moreover, ErbB1 over-
expressionwas not associatedwith tumor differentiation (P¼ 0.44), positivemargins (P¼ 0.53),
seminal vesicle invasion (P¼ 0.69), extraprostatic extension (P¼ 0.10), or preoperative PSA
(P¼ 0.18) in the hormone-naı̈ve group.
CONCLUSIONS. These findings are consistent with a model in which ErbB1 expression
increases during the development of the androgen-independent state, and suggest that drugs
targeted toward ErbB signaling could be of therapeutic relevance in the management of
advanced prostatic carcinoma. Prostate 66: 1437–1444, 2006. # 2006 Wiley-Liss, Inc.
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tumor progression
INTRODUCTION
Once prostate cancer progresses to a state of andro-
gen independence, therapeutic options are limited
and prognosis is invariably poor [1]. The molecular
mechanisms for the development of androgen resis-
tance are complex and largely unknown, but likely
involve peptide growth factors and their receptors [2].
The majority of androgen-independent prostate can-
cers (AIPCs) express androgen receptors (AR), sug-
gesting that AR signaling pathways are activated in the
absence of androgen. In this respect, a functional cross-
talk between growth factors and receptors of the c-ErbB
family and AR-activated pathways has been shown in
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clinical models [3–7]. The mammalian c-ErbB family
is comprised of four closely related receptor tyrosine
kinases (RTKs) that interact hierarchically in res-
ponse to multiple ErbB receptor ligands [8,9]. Mem-
bers of this family include ErbB1, more traditionally
known as the epidermal growth factor (EGF) receptor;
ErbB2, ErbB3, and ErbB4. Ligand binding to the
extracellular domain promotes receptor homo- and
heterodimerization, and as a consequence auto- and
trans-phosphorylation of specific tyrosine residues
on the cytoplasmic domain. These events result in
the activation of multiple signal transduction path-
ways, ultimately affecting many cellular functions
including cell migration, proliferation, and differentia-
tion [10].
ErbB receptor tyrosine kinases (RTKs) have been
implicated in the progression of a wide variety of
human cancers [11,12]. Growth factors of the EGF
family, such as EGF itself, transforming growth
factor-a(TGF-a), amphiregulin (AREG), and epiregulin
(EREG) heparin-binding EGF-like growth factor
(HB-EGF), could contribute to ErbB activation in
prostate cancer through autocrine and paracrine
mechanisms, resulting in increased proliferation, sur-
vival, motility, and invasion of tumor cells. Evidence
that such pathways are important in prostate cancer
include reports that prostate cancer cells express ErbB
family members in vitro and in vivo, and that EGF and
TGF-a are potent mitogens for prostatic cancer cells.
Moreover, expression of certain ErbB ligands in vivo
has been found to correlate with disease progression.
Thus, expression of TGF-awas shown to increase with
increasing degrees of prostatic malignancy [7], and
AREG has been reported to increase during progres-
sion fromnormal epithelium toprostatic intraepithelial
neoplasia to prostatic cancer [13].
Previous studies have indicated that ErbB1 is
overexpressed in primary and metastatic prostate
cancer specimens [7,14]. At the time these studies
were initiated, no studies had addressed the que-
stion of whether expression of ErbB1 is associated
with progression to androgen independence. Subse-
quently, one of two recent studies has suggested
that this is the case [15,16]. Given the inherent
biological variability of prostate cancer and the variety
of technical variables that can influence the results,
these findings merit further confirmation utilizing
samples that have been prospectively collected,
fixed, and processed in a uniform way. To this end,
we have utilized tissue microarrays (TMAs) to
investigate the potential role of ErbB1 in prostate
cancer progression by comparing its expression
in primary hormone-naı̈ve clinically localized pros-




and Prostate Sample Collection
As a source of hormone-naı̈ve prostate cancers, we
utilized tissue microarrays (TMAs) containing 433
cores representing cancer and benign tissue from 112
men who underwent radical retropubic prostatectomy
at the University of Michigan as the primary mono-
therapy (i.e., no adjuvant or neoadjuvant hormonal or
radiation therapy) for clinically localized prostate
cancer. It was assumed that these tumor samples were
hormone-naı̈ve, as these subjects had not yet been
subjected to antiandrogen therapy.As a source ofAIPC
samples,we studiedTMAs containing 323 cores (1 to 34
per patient) representing all the prostate cancer
metastasis sites and the prostate (if present) from
30 patients who died of advanced hormone-refractory
prostate cancer at our institution. Patients were
identified with hormone-refractory prostate cancer by
the Medical Oncology Service of the University of
Michigan Comprehensive Cancer Center and rapid
autopsies were performed to obtain samples as
described previously [17]. Both radical prostatectomy
and rapid autopsy series are part of the University of
Michigan Prostate Cancer Specialized Program of
Research Excellence (S.P.O.R.E.) Tissue Core. All
patients provided written informed consent, and this
study was approved by the Institutional Review Board
of the University of Michigan Medical School. Three
cores (0.6 mm in diameter) were taken from each
representative tissue block to construct the TMAs. The
TMA construction protocol has been described [18,19].
Detailed clinical, pathological, and TMA data are
maintained on a secure relational database as pre-
viously described [20].
Within the hormone-naı̈ve group, the median post-
surgery follow-up was 53 months (range¼ 1.9–
107.6 months) and the average age at surgery was
59.2 years (range¼ 43–80 years). Sixty-six percent of
tumors were organ-confined (stage pT2), 15.1% of
tumors had signs of local invasion (pT3), and 5.3% had
disease involving the bladder (stage pT4). Among the
112 patients, 28 had biochemical treatment failure
defined by a postoperative PSA >0.2 ng/ml.
Within the hormone-refractory group of 30 men,
28 were initially diagnosed with clinically localized
prostate cancer but developed widely disseminated
disease after 5–10 years. Two men presented with
disseminated disease. The median age at the time of
death was 71 years (range¼ 53–84 years). Of these
30 patients, 8 men underwent radical prostatectomy,
and17 receivedexternal beamradiationas their primary
treatment. Twenty-eight men received combination
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therapy, and all underwent hormonal manipulation.
Each of the eight men who underwent radical
prostatectomy as primary treatment experienced a
recurrence, received additional treatment (hormonal
manipulation with or without radiation and/or che-
motherapy), and then progressed to the hormone-
refractory state. The time that patients were treated
with androgen deprivation therapy ranged from 0 to
144 months with patients surviving in the hormone
refractory state (measured as time from first che-
motherapy) ranging from 0 to 61 months with a
hormone-refractory median survival of 14.5 months.
ErbB1Immunohistochemistry
TMAsfrombothgroupswere stained for expressionof
ErbB1 protein by means of a commercial kit utilizing a
highly specific mouse monoclonal antibody (Clone H11,
DAKO, Carpenteria, CA). All staining procedures were
carried out at room temperature, and all rinses were
performed with DAKO wash buffer unless otherwise
specified.TMAswere sectionedat 5m thickness,dewaxed
in three 2-min changes of xylene, rehydrated in graded
alcohols for 2 min each, subjected to peroxidase block
with 3% hydrogen peroxide for 5 min, rinsed, treated
with proteinase K (DAKO) for 10min, rinsed, incubated
with primary antibody or IgG1 isotype control for
60 min, rinsed, incubated with linker reagent (dextran
polymer conjugated with horseradish peroxidase and
affinity-purified goat anti-mouse immunoglobulins,
DAKO) for 30 min, rinsed, reacted with 3,30 diamino-
benzidine in chromogen solution (DAKO) for 5 min,
rinsed in water, dehydrated in graded alcohols,
incubated in three 2-min changes of xylene, and
mounted in Permount under glass coverslips. Sections
were examined by a pathologist (R.B.S.) in blinded
fashion using a previously validated web-based TMA
presentation tool, TMA Profiler (University of Michi-
gan, Ann Arbor, MI) [20]. Isotype controls were
uniformly negative (data not shown). ErbB1 staining
was evaluated on a scale of 1 (negative), 2 (weak), 3
(moderate), and 4 (strong) staining intensity. Staining
intensity for any given patient was defined as the
median of the intensity score assigned to each core from
that patient. In order to be scored, at least one of the
cores had to contain tumor. ErbB1 2 and ErbB1
>2 expression groups were analyzed for association
between ErbB1 protein expression (as assessed by
staining intensity) and hormone-refractory status (by
comparing hormone-naı̈ve and hormone-refractory
tumors) aswell as a variety of other clinical parameters.
Statistical Analysis
All statistical inference was performed at a signifi-
cance level of 0.05. EGFR staining was treated as a
dichotomous variable (mean staining 2 versus >2).
Associations between continuous variables with ErbB1
staining were assessed using a t-test; those between
categorical variableswith ErbB1 stainingwere assessed
using a chi-squared statistic. Across the tissue micro-
arrays, multivariate logistic regression analysis was
performed using ErbB1 staining as the response, and
AIPC (yes/no), age (defined as age at diagnosis for
the hormone-naı̈ve group and age at death for the
hormone-refractory group), and race (black/white)
as the variables. In addition, time to event analyses
were performed as well. For the nonmetastatic
(i.e., hormone-naı̈ve radical prostatectomy) TMAs,
the endpoint of interest was biochemical failure
(defined as elevation of PSA >0.2 ng/ml); for the
hormone-refractory metastatic TMAs, the endpoint
was death. The Kaplan–Meier method was used to
estimate distributions of time to event. Proportional
hazards regressionmodelswere used tomodel the time
to event as a function of univariate and multiple
covariates.
RESULTS
As reported previously [21–24], benign prostate
glands adjacent to and distant from tumor tissues
revealed strong ErbB1 staining, which was primarily
localized to the basal layer compartment of the
epithelium (Fig. 1A). In this compartment, ErbB1
protein expression was seen primarily in the form of
membranous staining with weak intracytoplasmic
staining, as reported previously [25].
ErbB1 expression in tumor cells was also predomi-
nantly localized to the cell membranes, though some
granular cytoplasmic staining was also observed
(Fig. 1B,D). ErbB1 expression in tumor tissues was
strongly associated with hormone-refractory status
(odds ratio¼ 6.67, 95% CI¼ (2.6, 17.4), P< 0.0001),
where the odds ratio compares the odds of high EGFR
expression in a randomly chosen hormone-refractory
tumor relative to a hormone-naı̈ve tumor, adjusting for
other covariates (Table I). In a proportional hazards
model for biochemical failure of hormone-naı̈ve clini-
cally localized prostate cancer, ErbB1 overexpression
was not a statistically significant covariate (Table II).
Moreover, ErbB1 overexpression was not associated
with tumor differentiation (Gleason score, P¼ 0.44),
positive margins (P¼ 0.53), seminal vesicle invasion
(P¼ 0.69), extraprostatic extension (P¼ 0.10), or pre-
operative PSA (P¼ 0.18) in the hormone-naı̈ve group
(Table III).
In the hormone-refractory group, there was a trend
toward poorer survival in individuals manifesting
high (>2) ErbB1 staining, as measured time from
chemotherapy to death. However, this result was not
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statistically significant (hazard ratio 1.32, 95% CI (0.59,
2.96), P¼ 0.44). Mean ErbB1 staining scores exceeded
the cutoff value of 2 for all metastatic sites, with the
highest mean values observed in soft tissue, bone and
lung (Table IV).
DISCUSSION
While a previous study had indicated that EGFR
expression increases during the natural history of
prostate cancer progression [7], this study could
not distinguish between androgen-dependent and
androgen-independent tumors. More recently, a study
appeared in which increased expression of ErbB1 was
correlated with the transition from hormone-naı̈ve to
androgen-independent status [14]. Given the impor-
tance of signaling through ErbB1 to a wide variety of
epithelial tumors via multiple potential mechanisms
(proliferation, survival, migration, and invasion), we
The Prostate DOI 10.1002/pros
TABLE I. Association Between ErbB1Expression and
Androgen-Independent (Hormone-Refractory) Status
Covariate Odds ratio 95% CI P-value
Androgen-independent
prostate cancer
6.67 (2.6, 17.4) 0.0001
Agea 1.03 (0.98, 1.09) 0.21
Race¼ black 1.33 (0/49, 3.59) 0.57
aAge is defined as age at diagnosis for the nonmetastatic
(hormone-naı̈ve) TMAs and age at death for the metastatic
(hormone-refractory) TMAs.
Fig. 1. ExamplesofErbB1stainingpatternsinbenignprostateglands,hormone-na|« veprostatecancer,andAIPC.Eachimageisrepresentative
of observationsmade onTMAs using the immunohistochemical staining protocol described in Materials and Methods.A: Normal prostate
glands adjacent to ahormone-na|« ve tumormanifesting strong stainingprimarily localized to thebasalcompartment.Tumorcellsdemonstrate
weak (grade 2) membranous staining.B: Hormone-na|« ve prostate cancer demonstrating strong (grade 4) membranous ErbB1 staining.C:
Androgen-independentprostate cancerdemonstrating lackof ErbB1expression (grade1).D: Androgen-independentprostate cancerdemon-
strating strong staining (grade4),whichin this tumorismembranous aswellas cytoplasmic.
TABLE II. ProportionalHazardsModel for Biochemical




ratio 95% CI P-value
ErbB1 staining >2 0.66 (0.22, 1.93) 0.45
Extraprostatic extension 1.50 (0.56, 427) 0.41
Positive surgical margin 4.16 (1.69, 10.27) 0.002
Seminal vesicle invasion 2.80 (0.86, 9.11) 0.09
Ln (prediagnosis PSAþ 1)a 1.36 (1.10, 1.66) 0.004
aPSA data were logarithmically transformed as shown because
the distribution of PSAwas skewed to the right andbecause some
PSA values were equal to zero.
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wished to attempt confirmation of this observation. To
accomplish this objective,weutilizedTMAs containing
two types of tumors: one containing clinically localized
primary prostate cancers surgically removed prior to
antiandrogen or radiation therapy, and another con-
taining primary and metastatic tumors from indivi-
duals who died of hormone-refractory prostate cancer.
Both TMAs were well characterized with respect to a
variety of clinical parameters. Our results clearly
confirmed the earlier findings of Di Lorenzo et al.
[14], as the odds ratio for overexpression (>2) of ErbB1
was 6.67 in androgen-independent relative to hor-
mone-naı̈ve prostate cancers (95% CI (2.6, 17.4),
P¼ 0.0001). Among hormone-naı̈ve tumors, no correla-
tions with any of the other clinical parameters could be
detected in this sample, suggesting that increased
expression of ErbB1 might be specifically connected
to the development of androgen independence. How-
ever, our data do not directly demonstrate a causal role
for ErbB1 in this process. For instance, it is possible that
upregulation of ErbB1 is a straightforward conse-
quence of transcriptional or post-transcriptional reg-
ulation related to androgen deprivation. Based on
recent reports, we consider this to be unlikely. Torring
et al. studied human androgen-sensitive CWR22
prostate cancer xenografts as a function of androgen
depletion via castration, followed by QRT-PCR for
multiple ErbB ligands and receptors [26]. While the
ErbB1 ligands EREG and AREG were significantly
increased in these xenografts as a function of androgen
deprivation, there was actually a twofold decrease in
ErbB1 expression within 2 weeks after castration, and
this decrease wasmaintained until the end of the study
(1 month after castration).
The fact that not all androgen-independent tumors
displayed increased expression of ErbB1 (for example,
see Fig. 1C) is likely a reflection of the fact that there are
many pathways to androgen independence [27], which
are reflected in substantial clinical and pathological
heterogeneity of androgen-independent metastatic
tumors, even within the same patient [17]. However,
it is noteworthy that the mean ErbB1 staining intensity
exceeded the cutoff point of 2 for all metastatic sites
(Table IV).
Our results confirm those of another recent
study, which was published after initiation of this
work. Hernes et al. studied 106 symptomatic AIPC
patients in whom prostatic biopsies were available
before the start of androgen deprivation and after the
development of AIPC. Expression of all four ErbB
receptors was assessed by immunohistochemistry. It
was found that only ErbB1 was significantly altered
during the transition to androgen independence, being
present in 69% of AIPC samples as opposed to 23% of
androgen-naı̈ve tumors [15]. That study contributes
additional negative results to a conflicting literature
regarding potential upregulation of ErbB2 in AIPC
[28–30], a controversy not addressed in the present
study.
Our results and those of Hernes et al. [15] differ
somewhat from another study of ErbB1 and ErbB2
expression in prostate cancers before and after hor-
mone therapy. In this smaller study of 49 patients, there
was no significant increase in ErbB1 or ErbB2 staining
with progression to androgen independence [16].
However, increased expression of ErbB1 or ErbB2 at
hormone relapse was associated with significantly
decreased survival in that study, consistent with
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TABLE III. Association Between ErbB1 Expression and Clinical Parameters in Hormone-
Na|« ve Clinically Localized Prostate Cancers
Clinical parameter ErbB1 >2 ErbB1 2 P-value for association
Age at diagnosis 62.0 58.5 0.15
Race¼ black 36.3 32.2 0.30
Gland weight 50.3 50.7 0.90
Gleason score 6.8 6.6 0.44
Maximum dimension 1.37 1.41 0.23
Seminal vesicle invasion 4.5% 6.6% 0.69
Positive surgical margin 27.2% 34.4% 0.53
Extraprostatic extension 13.6% 30.0% 0.10
Ln (prediagnosis PSAþ 1) 0.17 0.40 0.18
TABLE IV. ErbB1Staining IntensityDistributionsby Site of
Metastasis inAndrogen-Independent Prostate Cancers
No. of cores Median Mean Variance
Prostate 39 3 2.46 0.99
Soft tissue 49 3 2.86 0.83
Lymph node 62 2 2.36 1.58
Bone 26 3 2.96 1.24
Liver 61 3 2.54 1.12
Lung 37 3 3.19 0.71
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the non-significant trend to decreased survival we
observed in our ErbB1-overexpressing AIPC patients.
Our observations are consistent with a growing
body of mechanistic evidence linking ErbB signaling
and androgen independence, largely obtained uti-
lizing cultured prostatic carcinoma cell lines. Thus, it
has been shown that activation of ErbB signaling via
ErbB2 overexpression can result in activation of the
androgen receptor in an extracellular signal-responsive
kinase (ERK)-dependent fashion [31]. More recently, it
has been found that EGF triggers rapid association of
Src and ErbB1 with the androgen receptor (AR) and
estrogen receptor-b(ER-b) in the prostate cancer cell
line LNCaP, in a process involving tyrosine phosphor-
ylation of ERpreassociatedwithAR, but notwith Src or
ErbB1 [32]. Remarkably, formation of this complexwas
necessary for EGF-induced tyrosine phosphorylation
of ErbB1. Consistent with relevance of this pathway to
multiple tumor types, increasedSrc family kinase (SFK)
activitywas also observed in tamoxifen-resistantMCF-
7 mammary carcinoma cells, pharmacological inhibi-
tion of SFKs led to decreasedmotility and invasiveness
of the tamoxifen-resistant cells, and inhibition of ErbB
RTKs markedly potentiated the effects of SFK inhibi-
tion [33]. While not explicitly linked to androgen/
estrogen responses, we have recently demonstrated a
strong dependence of autocrine growth of normal
human skin-derived keratinocytes upon SFK activa-
tion, and we have implicated SFKs in the shedding of
AREG, a major autocrine ligand in keratinocytes [34].
Given the importance of autocrine and paracrine
growth regulation in prostatic carcinoma [7,35], it will
be of interest to examine the role of sex hormone
receptors and SFK in the regulation of ErbB ligand
shedding in pancreatic carcinoma cells.
Activation of ERK is a rapid downstream conse-
quence of ErbB1 activation in a wide variety of epi-
thelial cell types [36], suggesting that not only is AR is
required for ErbB-dependent ERK activation, but also
that ErbB activation activates AR transcriptional func-
tion via ERK. Consistent with this duality, hundreds
of target genes were found to be stimulated by both
EGF and dihydrotestosterone in an AR-dependent
fashion in an SV40-immortalized prostate epithelial
cell line [37]. Thus, while many important molecular
details remain to be elucidated, these results suggest a
multifaceted interaction between ErbB1 and AR in the
determination of prostatic epithelial cell responses, and
provide a framework for further mechanistic explora-
tion of ErbB-dependent androgen resistance.
The expression patterns of ErbB1 in normal prostatic
tissue versus prostatic carcinoma are of interest. In
normal prostate and normal-appearing perilesional
prostate tissue, we confirmed prior reports of
staining confined predominantly to the basal layer
compartment of the epithelium (Fig. 1A). The staining
in the benign glands was primarily but not completely
membranous. In contrast, patterns of ErbB1 expression
in tumor tissue were variable, with some tumors
demonstrating onlymembranous stainingwhile others
demonstrated membranous as well as cytoplasmic
staining (Fig. 1D). These results emphasize the impor-
tance of regulated ErbB1 expression and localization
for normal prostatic function, and emphasize a need for
better understanding of the downstream pathways
coupling ErbB1 to cellular responses in normal versus
malignant prostate tissue.
The correlation that we and others have observed
between increased ErbB1 expression and progression
to androgen independence suggests that EGFR-tar-
geted drugs could be of therapeutic relevance in the
management of advanced prostate cancer. However,
the marked heterogeneity of ErbB1 expression that we
have observed in this study indicates that it will be
important to target such therapy to those individuals
who are overexpressing ErbB1. Moreover, for prostate
cancer as well as other tumors in which aberrant ErbB
signalinghas been implicated, includingnon-small-cell
lung cancer [38], glioblastoma multiforme [39], and
breast cancer [40], patient-by-patient characterization
of post-receptor signaling alterations capable of over-
riding the therapeutic effects of ErbB1 RTK inhibition,
such as loss of PTEN [39], will likely be necessary to
identify appropriate candidates for therapeutic inhibi-
tion of ErbB1 activity in prostatic carcinoma patients.
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